Incidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis From MarketScan Database
Infections are common, recurrent, and burdensome after CAR T-cell therapy, driving substantial healthcare utilization and OOP costs. Risk-stratified prophylaxis and management strategies are needed throughout the treatment continuum.
Authors
- Daniel B. Chastain (ORCID: https://orcid.org/0000-0002-4018-0195)
- Dr Mohammed Zuber
- Lorenzo Villa Zapata
- Chia Jie Tan
- Shaimaa Elshafie
Institutions
- Emory University (US)
- University of Georgia (US)
- University of Utah (US)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jtct.2026.02.047
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00